← 返回

一种用于原代人 (CAR) T 细胞高级多重工程化的便捷病毒转导方法

英文原题:A convenient viral transduction based method for advanced multi-engineering of primary human (CAR) T-cells.

查看英文原题

A convenient viral transduction based method for advanced multi-engineering of primary human (CAR) T-cells.

PubMed 2024/11/28(内容时间) J Genet Eng Biotechnol

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

过去几十年的研究展示了T细胞工程在开发新型成功细胞疗法(如嵌合抗原受体[CAR] T细胞)方面的强大作用。尽管CAR-T 治疗血液系统恶性肿瘤取得临床成功,越来越多证据表明仍需进一步开展T细胞工程,以改善疗效和安全性,并拓展至实体瘤。工程化通常通过病毒递送转基因实现,但病毒载体容量有限,使高效、可重复地制备表达多种转基因的T细胞治疗产品在技术上颇具挑战。本文介绍一种便捷且高效的方法,可在T细胞中递送最多三种γ-逆转录病毒CAR载体。研究使用混合病毒载体实现这一目标;这些载体由双重或三重转导的稳定病毒生产细胞同时产生,且滴度较高。研究显示,与分别使用不同批次病毒进行常规双重或三重CAR转导相比,该方法在总体效率和可重复性方面更优。由于该方法稳健,可促进先进T细胞工程研究和开发,推动产生更有效、更安全的治疗方法。

展开英文摘要原文

The past decades have illustrated the power of T-cell engineering in the development of new and successful cell therapies, such as chimeric antigen receptor (CAR) T-cells. Despite clinical success in hematological malignancies, it also becomes increasingly clear that additional T-cell engineering will be required to improve efficacy and safety and expand the application to solid tumors.

Engineering is most often achieved by viral delivery of transgenes, however, viral vector capacity limitations make efficient and reproducible generation of multi transgene expressing T-cell therapeutics technically challenging.

We here describe a convenient and efficient method for the delivery of up to three -retroviral CAR vectors in T-cells.

We achieved this using virus vector mixtures that are simultaneously produced at high titers by double- or triple- transduced stable virus producer cells.

We show that this method is superior in overall efficiency and reproducibility to conventional double or triple CAR transductions, in which separate viral batches are used. Due to its robustness, this method can facilitate the research and the development for advanced T-cell engineering towards more effective and safe therapies.

论文信息

作者
van der Schans JJ、Katsarou A、Kladis G、Bar C、Ramirez MM、Themeli M、Mutis T
单位
Department of Hematology, Amsterdam UMC, Location VU University Medical Center, Cancer Center Amsterdam, Room CCA3.38, De Boelelaan 1117, Amsterdam 1081 HV, the Netherlands. Electronic address: j.vanderschans@amsterdamumc.nl.Netherlands
期刊
Journal, genetic engineering & biotechnology2024 Dec
原文标识
PubMed 39674638 · DOI 10.1016/j.jgeb.2024.100446